Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Genetic mapping and tailored antihypertensive therapy.

P Ferrari¹, G Bianchi

¹PRASSIS Research Institute Sigma-Tau (P.F.), Milan, Italy.

Cardiovascular Drugs and Therapy

|September 22, 2000

Summary

Personalized antihypertensive therapy is advancing, with genetic factors like adducin polymorphism influencing drug response. A new compound targeting renal Na-KATPase shows promise for treating hypertension linked to this genetic variation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action.

Journal of medicinal chemistry·1997

Same author

Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension.

Lancet (London, England)·1997

Same author

Immunoreactive prostate-specific antigen in pleural effusions.

Clinical chemistry·1997

Same author

Glucocorticoid receptor mutations in genetically hypertensive rats: markers of glucocorticoid insensitivity?

Biochemical Society transactions·1997

Same author

Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3'-polyphosphates.

The Journal of biological chemistry·1997

Same author

Nonacidotic proximal tubulopathy transmitted as autosomal dominant trait.

American journal of kidney diseases : the official journal of the National Kidney Foundation·1997

Area of Science:

Pharmacogenomics
Cardiovascular Medicine
Molecular Biology

Background:

Individual variability in antihypertensive drug efficacy and tolerability is a significant clinical challenge in essential hypertension.
Genetic heterogeneity of hypertension necessitates personalized treatment approaches.
Previous attempts to link phenotypic traits to drug responsiveness have yielded limited success.

Purpose of the Study:

To investigate the role of genetic polymorphisms in hypertension and their impact on antihypertensive therapy responsiveness.
To explore the association between adducin gene polymorphism, hypertension, sodium sensitivity, and diuretic response.
To evaluate a novel antihypertensive compound designed to correct specific genetic-related abnormalities.

Main Methods:

Analysis of genetic polymorphisms, including adducin, associated with hypertension in rat and human models.
Investigation of the underlying mechanism involving renal Na-KATPase and tubular sodium reabsorption.
Development and preclinical evaluation of a new antihypertensive compound in rats with adducin polymorphism.

Main Results:

A specific adducin gene polymorphism was identified, linked to both rat and human hypertension, sodium sensitivity, and diuretic response.
A likely mechanism involves a modification of renal Na-KATPase, increasing sodium reabsorption.
A novel compound effectively corrected renal Na-KATPase abnormalities and reduced blood pressure in rats with adducin polymorphism.

Conclusions:

Adducin gene polymorphism is a significant factor in hypertension and response to certain antihypertensive treatments.
Targeting renal Na-KATPase offers a potential therapeutic strategy for genetically defined hypertensive populations.
Clinical trials are underway to assess the efficacy of the novel compound in patients with varying adducin genotypes.

Related Experiment Videos